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Hydroxyurea, a drug widely used for treat-
ing myeloproliferative diseases, has also
been approved for the treatment of sickle
cell disease by raising fetal hemoglobin
(HbF). We have shown that nitric oxide
(NO) and the soluble guanylyl cyclase
(sGC) pathways are involved in hydroxyu-
rea induction of HbF levels in erythroid
progenitor cells (EPCs). We demonstrate
now that during erythroid differentiation,
endothelial NO synthase mRNA and pro-
tein levels decline steadily, as does the
production of NO derivatives and cyclic
adenosine monophosphate (cAMP) lev-
els, but guanosine 3,5-cyclic monophos-
phate (cGMP) levels are stable. Hydroxyu-
rea increased intracellular cGMP levels
and cAMP levels in EPCs. The NO donor,
DEANONOate, induced much higher
cGMP levels, but reduced cAMP levels.
Hydroxyurea (1 mM) induced production
of approximately 45 pM cGMP/minute/ng
of purified sGC, similar to induction by
1 M DEANONOate. We found that hy-
droxyurea and ProliNONOate produced
iron-nitrosyl derivatives of sGC. Thus, we
confirm that hydroxyurea can directly in-
teract with the deoxy-heme of sGC, pre-
sumably by a free-radical nitroxide path-
way, and activate cGMP production. These
data add to an expanding appreciation of
the role of hydroxyurea as an inducer of
the NO/cGMP pathway in EPCs. These
mechanisms may also be involved in the
cytostatic effects of hydroxyurea, as well
as the induction of HbF. (Blood. 2008;111:
1117-1123)
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Introduction
Hydroxyurea is a cytostatic drug that has been used to treat a
variety of myeloproliferative diseases but has recently been
shown to be effective in elevating fetal hemoglobin (HbF) as a
therapy for individuals with sickle cell disease.1,2 An intracellu-
lar signaling pathway including soluble guanylyl cyclase (sGC)
and guanosine 3,5-cyclic monophosphate (cGMP)–dependent
protein kinase (PKG) was reported to induce the expression of
the gamma-globin gene (HBG1) of HbF in human erythroid cell
lines and primary cells.3 We demonstrated that hydroxyurea
effects include the nitric oxide (NO)–dependent activation of
sGC in cultured CD34 human erythroid precursor cells.4
Hydroxyurea has been reported to significantly increase NO and
cGMP in the blood of patients with sickle cell anemia.5 In
addition, cGMP levels were found to be significantly higher in
the red blood cells (RBCs) of patients with sickle cell anemia
than those of healthy individuals, and were further increased in
RBCs of patients with sickle cell anemia on hydroxyurea therapy.6
The cyclic adenosine monophosphate (cAMP)–dependent pathway,
which is independent of the mitogen-activated protein kinase (MAPK)
pathways, appears to play a negative role in gamma-globin gene
expression in K562 erythroleukemia cells.7
It is established that hydroxyurea inhibits ribonucleoside diphos-
phate reductase, thereby blocking DNA synthesis and repair.8
Hydroxyurea is converted to a free radical nitroxide in vivo and
transported by diffusion into cells, where it quenches the tyrosyl
free radical at the active site of ribonucleotide reductase, inactivat-
ing the enzyme.9 Transient nitroxide-like radicals from hydroxy-
urea have been detected in the reaction of hydroxyurea with protein
R2 from Escherichia coli and mouse, indicating that 1-electron
transfer from hydroxyurea to the tyrosyl radical is the dominating
mechanism in the inhibitor reaction.10 An electron spin resonance
spectroscopic study also demonstrated that NO was generated from
hydroxyurea.11 Both NO gas and NO generated by activated
macrophage lysates inhibit tumor cell ribonucleotide reductase.12
Cytostasis by activated macrophages and by hydroxyurea appears
to have comparable mechanisms, including, but probably not
limited to, inhibition of ribonucleotide reductase.13 These results
suggest that NO production from hydroxyurea may be the molecu-
lar basis of the pharmacologic and antitumor activity of
hydroxyurea.14
To define the relationship between hydroxyurea stimulation of
erythroid progenitor cells to increase HbF and NO pathways, we
investigated the NO production and NO synthase expression during
erythroid differentiation. Hydroxyurea elevated intracellular cGMP
and cAMP levels of human erythroid progenitor cells. Using
purified sGC in solution with GTP, as substrate, we found that
hydroxyurea induced production of cGMP. We also measured the
formation of the iron-nitrosyl complex as the end product of the
reaction of hydroxyurea and the heme of sGC. These results help in
elucidate the hydroxyurea role in sGC induction as well as
providing a mechanism by which hydroxyurea may generate
bioactive NO.
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Methods
The 2-phase liquid erythroid cell cultures
Peripheral blood mononuclear cells were isolated from buffy coats of
healthy donors. We performed a 2-phase liquid culture protocol previously
described.4 Briefly, after incubation in phase I culture in the absence of
erythropoietin, CD34 cells were harvested by centrifugation and purified
by negative selection using the StemSep Cell Separation method (Stem Cell
Technologies, Vancouver, BC). The CD34 cells were resuspended in the
phase II medium, which contained a mixture of cytokines, including human
recombinant erythropoietin (Amgen, Thousand Oaks, CA). The concentra-
tion of total proteins and hemoglobins in erythroid cells plated in wells of a
96-well microplate (1  105 cells/well) were assessed using an 8453
UV/Visible Spectrophotometer (Hewlett-Packard, Waldbronn, Germany).
Cells were subsequently cultured for 16 hours in 200 L of fresh medium
containing an appropriate concentration of bradykinin (Alexis Biochemi-
cals, San Diego, CA). The activated cells in wells were washed twice with
Dulbecco phosphate-buffered saline (PBS; Invitrogen, Carlsbad, CA), and
then 10 M diaminofluorescein (DAF-2; Alexis Biochemicals) and 1 mM
l-arginine (Sigma, St Louis, MO) were added. After incubation for a further
2 hours, the supernatants (an aliquot of 10 L of each cell supernatant) were
transferred to black microplates, and the fluorescence of NO/DAF-2
interaction was measured with a fluorescence microplate reader calibrated
for excitation at 485 nm and emission at 538 nm.
Isolation of total RNA
For isolation of total RNA from erythroid cells we used the RNeasy
procedure (Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. The concentration and integrity of total RNA were assessed using an
8453 UV/Visible Spectrophotometer (Hewlett-Packard) and Agilent 2100
Bioanalyzer (Agilent Technologies, Waldbronn, Germany). A total of 1 g
of total RNA was reverse transcribed with SuperScript II RNase H
Reverse Transcriptase kit (Invitrogen).
Quantitative PCR
Quantitative real-time polymerase chain reaction (PCR) assay of human
inducible NO synthase (iNOS) mRNA transcripts was carried out with the
use of gene-specific double-fluorescently labeled probe (5-CAA GAG
CCA GAA GCG CTA TCA CGA AGA T-3) in a 7700 Sequence Detector
(Applied Biosystems, Foster City, CA). The specific primers of iNOS
(sense: 5-AGG TCG AGG ACT ATT TCT TTC AGC-3; antisense:
5-CTG TCC TTC TTC GCC TCG TAA G-3) and TAQMAN probes
(synthesized by the National Institute of Diabetes and Digestive and Kidney
Diseases [NIDDK] core oligonucleotide facility) were designed using
Primer Express software and prepared on an ABI 394 synthesizer (both
from Applied Biosystems). The specific primers of human endothelial NO
synthase (eNOS) mRNA transcript and TAQMAN probe were designed as
previously described.15 Platinum Quantitative PCR SuperMix-UDG (Invitro-
gen) was used, containing a final concentration of 200 M 2-
deoxynucleoside 5-triphosphates (dNTPs is a mix of dATP, dCTP, dGTP,
and dTTP), 0.5 M Rox reference dye (Invitrogen), 0.2 M each of
TAQMAN probe, sense, and antisense primers. Expression levels were
determined using the associated SDS software (ABI Prism; Applied
Biosystems) and Microsoft Excel (Redmond, WA).
Ozone-based chemiluminescent determination of nitrite in
supernatant of cell culture
For nitrite (NO2) and total NO (nitrate plus nitrite plus nitrosothiols equals
NOx) measurements in supernatant of erythroid cell cultures, erythroleuke-
mic and erythroid cells in 6-well plates were washed once with Dulbecco
PBS. After 2 hours, the supernatant was immediately frozen on dry ice and
stored at 80°C. NO2 is measured as already described,16 whereas NOx
was measured using vanadium (III) chloride in hydrochloric acid at 90°C
with the Sievers Model 280 NO analyser (Sievers, Boulder, CO). Helium
was bubbled through the reaction mixture. I3-based chemiluminescence
assay was modified with acidified sulfanilamide and HgCl2 as follows:
purified sGC (300-350 nM, diluted in PBS without Ca2 and Mg2) was
treated with hydroxyurea and ProliNONOate (t1/2  1.8 seconds at 37°C,
2 M of NO released per mole of NO donor; Alexis Biochemicals) for an
incubation time of 10 minutes at 37°C. Samples were transferred on dry ice
for freezing. For analysis, samples were thawed at room temperature and
acidified sulfanilamide was quickly added (final concentration, 0.5%) as
well as HgCl2 (final concentration, 5 mM). Acidified sulfanilamide reacts
with nitrite to form a diazonium compound that is not reduced to NO in the
I3 chemiluminescent assay (and consequently does not have a signal). NO
concentrations from the samples containing acidified sulfanilamide and
HgCl2 represent plasma iron-nitrosyl levels only.17 After 2 minutes, samples
were transferred on wet ice and measured with NO analyzer.
Immunoblotting
Cell lysates were heated to 90°C for 10 minutes in LDS sample buffer
(Invitrogen). Proteins were then separated on 3% to 8% NuPAGE Tris
acetate gels and transferred onto polyvinylidene difluoride membranes
(Invitrogen), and then probed in immunoblots using eNOS (BD Transduc-
tion Laboratories, San Jose, CA) and actin (Santa Cruz Biotechnology,
Santa Cruz, CA) monoclonal antibodies according to the protocols provided
by the suppliers. The membrane was incubated with a primary antibody
overnight at 4°C, and afterward 1 hour at room temperature with a
horseradish peroxidase–conjugated sheep anti–mouse IgG. Proteins were
visualized by chemiluminescence (ECL plus; Amersham Biosciences,
Piscataway, NJ). The intensities of immunoreactive bands in Western blots
were analyzed by using the NIH IMAGE program (FluorChem Imaging
system; Alpha Innotech, San Leandro, CA).
High-performance liquid chromatography
Erythroid cells were harvested at different time points during erythroid
differentiation. To perform high-performance liquid chromatography (HPLC)
quantitation of hemoglobin, we separated hemoglobins by cation exchange
HPLC of supernatants from cell lysates. The pelleted cells were resus-
pended, lysed in sterile distilled water, and centrifuged in 0.45 m filter unit
(Millipore, Bedford, MA) for 10 minutes at 4°C. The filtrate was
chromatographed on a PolyCAT A 20  4.0 mm column (PolyLC, Colum-
bia, MD) fitted to a Gilson HPLC system (Gilson, Middleton, WI)
developed with a sodium acetate gradient in 20 mM BisTris buffer (pH
6.55-6.96). Peak areas were integrated with the use of the system software.
Human eNOS immunoassay
Erythroid cells were washed 2 times in PBS, the supernate was discarded,
and the cells were lysed at 4°C with cell lysis buffer (R&D Systems,
Minneapolis, MN), 1 mL of buffer per 1  106 cells. The cells were
centrifuged at 300g for 5 minutes, and the supernate was removed and
assayed immediately or aliquoted and stored at 20°C or less for up to
24 hours. eNOS protein levels were measured using the human eNOS
immunoassay (R&D Systems) according to the protocol of the supplier.
cGMP and cAMP measurements
Erythroid progenitor cells were treated with hydroxyurea or
DEANONOate (sodium(Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-dio-
late; t1/2  2 minutes at 37°C, 1.5 M of NO released per mole of NO donor;
Alexis Biochemicals) at day 4 of culture and about 1  106 cells were
harvested at different time points. Cells were pretreated 30 minutes with
3-isobutyl-1-methylxanthine (Sigma) at a final concentration of 0.5 mM to
inhibit phosphodiesterase activity. Cyclic nucleotides were measured in cell
extract by radioimmunoassay using specific antisera provided by Albert
Baukal (National Institute of Child Health and Human Development
[NICHD], Bethesda, MD). Mixtures of purified sGC (Alexis Biochemi-
cals), 3 mM MgCl2 (cofactor), and 1 mM GTP (substrate) were treated with
hydroxyurea and DEANONOate, and incubated for 10 minutes at 37°C
(shaking on 600 rpm). After incubation, mixtures were diluted in 1 mL cold
PBS (pH  7.4; without Mg2 and Ca2). A total of 10 L acidmix
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(two-thirds triethylamine and one-third acetic anhydride) was added to a
0.5-mL mixture with sGC in glass tubes. After vortexing for 7 to
10 seconds, 0.1 mL of mixture was transferred in new glass tubes. Tubes
were covered with Parafilm (American National Can Company, Chicago,
IL) and frozen at 80°C for storage and thawed before measurement by
radioimmunoassay.
Statistical analysis
The 1-way analysis of variance (ANOVA) and Dunnett post tests were
applied using Prism 4 software (GraphPad Software, San Diego, CA).
Results
NOS activity in erythroid cells during differentiation
After isolation of CD34 progenitor cells at day 0 (about 90%
purity), erythroid differentiation was stimulated by a mixture of
cytokines, including erythropoietin. We observed a fall in both
NO2 and NOx levels during differentiation of erythroid cells
(Figure 1A). An increase in NOx levels occurred at day 18, which
paralleled the marked decrease in cell number and increased
apoptosis of erythroid cells at this time. The levels of hemoglobin
(primarily HbA), a scavenger of NO, were enriched during
erythroid differentiation of CD34 cells as expected (Figure 1B),
as measured by spectrophotometry and HPLC. To show eNOS
activity, we treated erythroid progenitor cells with the well-known
eNOS inducer bradykinin. The dose-dependent induction of extra-
cellular NO levels was observed during bradykinin treatment of
erythroid cells as measured by the fluorescent indicator DAF-2
(Figure 1C). Induction of intracellular NO levels was also revealed
during bradykinin treatment as measured by the fluorescent indica-
tor DAF-2 diacetate (data not shown).
NOS levels in erythroid cells during differentiation
It has been reported that human RBCs express an active and
functional eNOS, which is localized in the plasma membrane and
the cytoplasm of RBCs.18 According to our experiments, the
highest eNOS mRNA levels were detected in CD34 progenitor
cells at day 0. After that, a prominent decline of eNOS mRNA
levels in erythroid cells was observed, with a slight elevation at day
14 associated with the start of apoptosis (Figure 2A). Insignificant
levels of iNOS mRNA was found during maturation of erythroid
cells but with also an apparent slight increase at day 14 (Figure 2B).
We did not detect nNOS mRNA and protein in erythroid cells (data
not shown). A continuous fall of eNOS protein levels was
demonstrated during the maturation of erythroid cells (Figure
2C,D). At day 14, eNOS protein is still detected in erythroid cell
cultures by enzyme-linked immunosorbent assay (ELISA; Figure
2C) but no longer observed by the less-sensitive Western blotting
technique (Figure 2D).
Intracellular cyclic nucleotides levels in human erythroid
progenitor cells
We have previously shown that hydroxyurea and the NO donor
CysNO (t1/2  30 minutes) increased cGMP levels in erythroid
cells.4 Here, we use the cyclic nucleotide–specific radioimmunoas-
says to compare cGMP and cAMP production. We found a
continuous fall in cAMP levels in contrast to steady levels of cGMP
during erythroid differentiation (Figure 3A). The cGMP levels in
erythroid progenitor cells were similar to primitive CD34 progeni-
tor cells, whereas both cGMP and cAMP levels were minor in
mature RBCs compared with erythroid progenitor cells (data not
shown). After 4 hours of incubation, hydroxyurea did not signifi-
cantly inhibit cell growth by day 4 of erythroid cell culture,
whereas hydroxyurea dose-dependently inhibited erythroid cells
growth by 30% to 40% after 24 and 48 hours of incubation (Figure
3A). The effects of the 3 cytotoxic agents 5-azacytidine, hydroxyu-
rea, and butyric acid on cell viability in the same erythroid cultures
are already reported by our lab.19 Briefly, hydroxyurea
(20-100 M) does not show a consistent and reproducible impact
on cell number, whereas both 5-azacytidine (5-20 M) and butyric
acid (0.1-1.0 mM) addition resulted in reduced cell counts on the
fourth day after adding erythropoietin to the cultured cells.
Figure 1. Characterization of 2-phase liquid culture of erythroid cells. (A) NO
production during erythroid differentiation (per 1  106 cells; n  3). (B) Total globins
per total protein levels during erythroid differentiation of CD34 cells. The heme
group of globins gives a maximum absorbance at 415 nm, while 280 nm is the
maximum absorbance for most proteins (because of tryptophan, tyrosine, and
phenylalanine; n  3). HPLC analyses of HbA and HbF during erythroid differentia-
tion (n  4). (C) Detection of extracellular NO levels with fluorescent indicator DAF-2
in erythroid progenitor cells at day 6, during treatment with bradykinin (n  3). Values
are means ( SEM). *P  .05 and **P  .01 compared with cells at day 4 (B) and
untreated with bradykinin (C).
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Hydroxyurea increased intracellular cGMP levels (60-80 fmol/105
cells; Figure 3B) as well as cAMP levels (1000-1800 fmol/105
cells; Figure 3C), thereby reducing the cGMP/cAMP ratio, in
human erythroid progenitor cells after 4 hours of incubation. The
NO donor, DEANONOate, induced much higher intracellular
cGMP levels (600 fmol/105 cells, Figure 3B), but reduced
cAMP levels (100-150 fmol/105 cells, Figure 3C). The induced
intracellular cGMP levels by hydroxyurea and DEANONOate,
corresponded to the increase of extracellular cGMP levels of 30 to
50 fmol/105 cells and 400 to 1600 fmol/105 cells, respectively, after
2 hours of incubation.
Induction of purified sGC by hydroxyurea and NO donors
We hypothesized that hydroxyurea could also react with the ferrous
heme group of sGC, resulting in iron-nitrosylation and enzymatic
activation, in a way similar to the reaction of hydroxyurea and
deoxyhemoglobin to form iron-nitrosyl-hemoglobin (HbNO).20
Using purified sGC in solution, we found by radioimmunoassay
that 1 mM hydroxyurea induced production of approximately
45 pM cGMP/minute/ng sGC (average value for all presented
quantities of sGC), similar to induction by 1 M of an NO donor,
DEANONOate (Figure 4A,B). Also, we demonstrated dose-
dependent effects of hydroxyurea and the NO donor on cGMP
production: 0.5 mM hydroxyurea incubated with 10 and 50 ng of
sGC induces 29 and 12 pM cGMP/minute/ng sGC, respectively,
whereas 10 M DEANONOate induces 160 and 532 pM cGMP/
minute/ng sGC, respectively (Figure 4A,B). Under the same
conditions, without sGC, hydroxyurea (0.001-100 mM) failed to
create NO as measured via nitrite levels by NO analyzer (data not
shown). Sodium nitrite (0.001-10 mM) did not induce cGMP
production of purified sGC as measured by radioimmunoassay
(Figure 5A), which confirmed a primal role of NO (as a part of
hydroxyurea molecule) in hydroxyurea induction of sGC.
In order to test for NO binding to the deoxy-heme of sGC, we
measured the formation of the iron–nitrosyl complex with the
modified tri-iodine–based chemiluminescence assay (with displace-
ment of NO/thiol groups with HgCl2) following the induction of
purified sGC by hydroxyurea.17 We found that 10 mM of hydroxy-
urea and 10 M ProliNONOate produced about 3 nM and 30 nM
iron-nitrosyl levels per microgram of purified sGC, respectively
(100 mM of hydroxyurea induces about 5 nM iron-nitrosyl levels;
Figure 5B). These data are consistent with earlier studies showing
that hydroxyurea reacts with deoxyhemoglobin in vitro and con-
verts 2% to 6% of the total hemoglobin to HbNO.20 In our studies,
hydroxyurea reacted with deoxy-heme of sGC to convert 3% to 6%
of the total heme to the iron-nitrosyl complex, whereas ProliNONO-
ate converted 18% of the total heme of sGC to the same complex
(Figure 5B). Therefore, we verified the hypothesis that hydroxy-
urea can directly interact with the deoxy-heme of sGC, generating
the iron-nitrosyl complex, and consequently activate cGMP
production.
Discussion
Human erythroid progenitor cells contain eNOS mRNA and
protein and demonstrate eNOS activity. We observed a fall in
eNOS mRNA and protein levels as well as its activity during
erythroid differentiation, concomitantly with the elevation of
hemoglobin levels. We found a continuous decrease in cAMP high
levels in contrast to steady low levels of cGMP during erythroid
differentiation. So, the eNOS protein level, as well as cAMP levels,
continuously decline during erythroid differentiation. Their activity
and presence is parallel to gamma-globin gene expression, which
also declines during erythroid differentiation. Hydroxyurea, a drug
which stimulates gamma-globin gene expression, increased steady
intracellular cGMP levels as well as cAMP levels in human
erythroid progenitor cells, whereas the NO donor increased intracel-
lular cGMP levels but reduced cAMP levels. The cAMP signal is
adjusted by cAMP degradation determined by phosphodiesterases
3 (PDE3) in erythroid cells, where the PDE3 is inhibited due to
activation of sGC.21 Using purified sGC we demonstrated that
Figure 2. NOS levels during differentiation of ery-
throid cells. (A) eNOS mRNA levels during differentia-
tion of erythroid cells. (B) iNOS mRNA levels during
differentiation of erythroid cells; (C,D) eNOS protein
levels during differentiation of erythroid cells: as mea-
sured by ELISA (C) and Western blotting compared with
actin protein levels as a control (D). Vertical lines have
been inserted to indicate a repositioned gel lane (n  3).
Values are means ( SEM). **P  .01 compared with
cells at day 0.
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hydroxyurea could directly interact with deoxy-heme of sGC,
generating the iron-nitrosyl complex, and consequently activating
cGMP production. These results are all consistent with an NO-
dependent sGC mechanism for the elevation of HbF in erythroid
progenitor cells.
It has been demonstrated that human RBCs contain iNOS and
eNOS as well as calmodulin, suggesting that RBCs may
synthesize their own NO.22 This notion was supported by the
observation that RBCs have an active eNOS protein.23 However,
it was later reported that RBCs possess iNOS and eNOS, but the
proteins are without catalytic activity.24 Recent studies revealed
eNOS protein in the cytoplasm and in the internal side of RBC
membranes as measured by activity.18 However, we demon-
strated the continuous decline of eNOS presence and activity
throughout erythroid differentiation, suggesting that such activ-
ity may be a residual of eNOS production at an earlier stage.
Inhibition of NOS partially reversed the hydroxyurea effects on
HbF synthesis in erythroid burst-forming unit (BFU-E) colo-
nies,25 but did not decrease NOx production in RBCs during
incubation with hydroxyurea.26 In contrast, NOS activity has
been reported to be higher in RBCs of healthy individuals and
patients with sickle cell disease on hydroxyurea therapy.27 This
is in accordance with results that L-arginine increases serum
NOx production only in combination with hydroxyurea in
patients in steady state.28 It has been reported that hydroxyurea
increases NO production in bone marrow endothelial cells.16
The paracrine effect of endothelial cell–derived NO on erythroid
cells may be more physiologically relevant in sGC stimulation
than hydroxyurea interaction with deoxy-heme of sGC.
Recent studies indicated that hydroxyurea increased HbF
levels through the NO-dependent activation of sGC in erythroid
cells.4 It has been shown that both sGC activators and cGMP
induce gamma-globin gene expression in K562 erythroleukemia
cells and primary erythroblasts,3 whereas the cAMP-dependent
pathway plays a negative role in gamma-globin gene expression
in K562 cells.29 Hydroxyurea increased cGMP levels in human
erythroid progenitor cells, while gamma-globin induction by
both hydroxyurea and NO donor was prevented by sGC
inhibitors.4 cGMP levels correlated with HbF levels in hydroxy-
Figure 3. Intracellular cGMP and cAMP levels in human erythroid progenitor
cells. (A) Intracellular cGMP and cAMP levels in erythroid progenitor cells (left
y-axis). Hydroxyurea (HU) dose-dependently inhibits erythroid cells growth after
24 and 48 hours of incubation (right y-axis). (B) Hydroxyurea (30 M) and
DEANONOate (50 M) increased cGMP levels during 4 hours of incubation of human
erythroid progenitor cells at day 4 of phase II liquid culture. (C) Hydroxyurea (30 M)
and DEANONOate (50 M) increases and inhibits, respectively, cAMP levels during
4 hours of incubation of human erythroid progenitor cells at day 4 of phase II liquid
culture (n  3). Values are means ( SEM).
Figure 4. In vitro induction of purified sGC by hydroxyurea and NO donors.
(A) Mixtures of purified sGC (0.5,1, 5, 10, and 50 ng), 3 mM MgCl2, and 1 mM GTP
were treated with DEANONOate (1 and 10 M) during 10 minutes of incubation.
(B) Mixtures of purified sGC (0.5, 1, 5, 10, and 50 ng), 3 mM MgCl2 and 1 mM GTP
were treated with hydroxyurea (0.5 and 1 mM) during 10 minutes of incubation.
Background with 0 ng purified sGC, and the mixtures, was subtracted from the results
(n  3). Values are means  SEM.
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urea-treated patients with sickle cell disease.6 Hydroxyurea
therapy also concomitantly increased NO, cGMP, and HbF
levels in the same patients.5 During erythroid differentiation
adenylate cyclase activity, cellular cAMP concentrations and
cAMP phosphodiesterase activity have been reported to decline
in a synchronized manner.30 In addition to our findings in this
and a previous publication,4 there have been 2 reports of cAMP
increasing HbF levels. Ikuta’s group31 has reported that expres-
sion of the gamma-globin gene is induced upon activation of the
cAMP pathway, while Dover and colleagues32 found that
adenylate-cyclase inhibition markedly decreased HbF induction
by hydroxyurea in human erythroid precursor cells. They also
reported that hydroxyurea failed to significantly stimulate
adenylate-cyclase activity,32 whereas we demonstrated that
hydroxyurea stimulated cAMP production in erythroid progeni-
tor cells. While our results are based on studies of erythroid
progenitor cells, the above-mentioned studies31,32 are performed
on erythroid precursor cells with lower cAMP and elevated
hemoglobin levels,4 a potent NO scavenger. NO reduces cAMP
levels in erythroid cells, whereas cAMP appears to enhance NO
formation.33 The NO-mediated cAMP-reducing mechanisms
may operate as a negative feedback in control of cAMP levels.
Furthermore, the cGMP response to NO was higher in cells with
elevated cAMP levels.34 As already revealed, the cAMP-
hydrolyzing PDE isozyme is a cGMP-inhibitable PDE3B in
erythroid cells.29 Thus, the cAMP-dependent pathway can be
simultaneously triggered since cGMP controls PDE3B activity.
Therefore, it appears that hydroxyurea’s parallel activation of
the linked cGMP- and cAMP-regulatory pathways increases
cyclic nucleotide related gamma-globin induction.
The reaction of NO with deoxyhemoglobin produces HbNO.35
Hydroxyurea initially oxidizes deoxyhemoglobin to methemoglobin
and then reduces methemoglobin to deoxyhemoglobin during HbNO
formation, progressing by inner-sphere mechanisms, where the NO
group derives from the NHOH portion of hydroxyurea.20,36 In
contrast, addition of NO to deoxyHbA quickly produces only HbNO. It
has been also observed that reaction products of hydroxyurea and
deoxyHbA do not arise from the direct reaction of NO.20 sGC permits
NO to bind directly to its ferrous deoxy-heme, activating the enzyme.37
Similar to the reaction of hydroxyurea and deoxyhemoglobin to form
HbNO, we demonstrate that hydroxyurea can also directly iron-
nitrosylate sGC and accordingly trigger cGMP production. Erythroid
cells, as well as RBCs, contain high levels of sGC subunits representing
an alternative locus for hydroxyurea interaction with deoxy-heme.3,38 It
has been shown that nitrite ions increase blood flow in the human
circulation as well as vasodilatation of rat aortic rings. Formation of both
NO and NO-modified hemoglobin results from the nitrite reductase
activity of deoxyhemoglobin.39 It has been also reported that deoxygen-
ated myoglobin is an efficient nitrite reductase that generates bioavail-
able NO.40 Studies of nitrite activation of sGC demonstrated that nitrite
alone (at concentration of 0.1 mM) moderately activated sGC in
solution.41 In our in vitro studies nitrite failed to induce cGMP, in
purified sGC in solution, confirming a major role of the NO molecule in
hydroxyurea interaction with sGC. Moreover in a recent study, inor-
ganic nitrite (in the range of 0.01 mM-1 mM) also failed to increase sGC
activity, but in combination with ascorbate increased sGC activity.42
A total of 2 distinct mechanisms have been proposed to explain in vitro
nitrate activation of sGC: nitrate reacts with a sGC cysteine residue to
yield NO or activation of sGC by an NO-independent mechanism.43
Our observations provide evidence for hydroxyurea stimula-
tion of the NO/cGC pathway, as well as interaction between
hydroxyurea and sGC. In addition to the possibility of some
NOS presence and activity in mature RBCs, these data show
strong eNOS protein levels and function in more primitive
human erythroid progenitor and precursor cells, where control
of gene expression occurs. The correlation between the levels of
cyclic nucleotides and hydroxyurea induction illustrate their
participation in hydroxyurea effects on erythroid and endothe-
lial cells. Hydroxyurea stimulation of NO and cyclic nucleotide
production may be involved in the therapeutic activity of
hydroxyurea as both a cytostatic agent and a pharmacologic
means to elevate fetal hemoglobin.
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Figure 5. In vitro interaction between hydroxyurea and heme of sGC. (A) Sodium
nitrite (0.001-10 mM) did not induce cGMP production of purified sGC as measured
by radioimmunoassay. (B) Using tri-iodine–based reductive chemiluminescence
assay, we measured the formation of the iron-nitrosyl complex during treatment of
purified sGC with hydroxyurea and ProliNONOate. The numbers above columns
represent percentage of conversion of deoxy-heme to the iron-nitrosyl complex
(n  3). Values are means ( SEM).




 http://ashpublications.org/blood/article-pdf/111/3/1117/1305799/zh800308001117.pdf by guest on 27 M
arch 2021
References
1. Charache S, Terrin ML, Moore RD, et al. Effect of
hydroxyurea on the frequency of painful crises in
sickle cell anemia: investigators of the Multicenter
Study of Hydroxyurea in Sickle Cell Anemia.
N Engl J Med. 1995;332:1317-1322.
2. Atweh GF, Schechter AN. Pharmacologic induc-
tion of fetal hemoglobin: raising the therapeutic
bar in sickle cell disease. Curr Opin Hematol.
2001;8:123-130.
3. Ikuta T, Ausenda S, Cappellini MD. Mechanism
for fetal globin gene expression: role of the
soluble guanylate cyclase-cGMP-dependent pro-
tein kinase pathway. Proc Natl Acad Sci U S A.
2001;98:1847-1852.
4. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hy-
droxyurea induces fetal hemoglobin by the nitric
oxide-dependent activation of soluble guanylyl
cyclase. J Clin Invest. 2003;111:231-239.
5. Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E,
Winter WP, Castro O. Nitric oxide and cyclic GMP
levels in sickle cell patients receiving hydroxyu-
rea. Br J Haematol. 2002;119:855-857.
6. Conran N, Oresco-Santos C, Acosta HC, Fattori
A, Saad ST, Costa FF. Increased soluble guany-
late cyclase activity in the red blood cells of sickle
cell patients. Br J Haematol. 2004;124:547-554.
7. Inoue A, Kuroyanagi Y, Terui K, Moi P, Ikuta T.
Negative regulation of gamma-globin gene ex-
pression by cyclic AMP-dependent pathway in
erythroid cells. Exp Hematol. 2004;32:244-253.
8. Krakoff IH, Brown NC, Reichard P. Inhibition of
ribonucleoside diphosphate reductase by hy-
droxyurea. Cancer Res. 1968;28:1559-1565.
9. Yarbro JW. Mechanism of action of hydroxyurea.
Semin Oncol. 1992;19:1-10.
10. Lassmann G, Thelander L, Graslund A. EPR
stopped-flow studies of the reaction of the tyrosyl
radical of protein R2 from ribonucleotide reduc-
tase with hydroxyurea. Biochem Biophys Res
Commun. 1992;188:879-887.
11. Sakano K, Oikawa S, Hasegawa K, Kawanishi S.
Hydroxyurea induces site-specific DNA damage
via formation of hydrogen peroxide and nitric ox-
ide. Jpn J Cancer Res. 2001;92:1166-1174.
12. Lepoivre M, Flaman JM, Bobe P, Lemaire G,
Henry Y. Quenching of the tyrosyl free radical of
ribonucleotide reductase by nitric oxide. Relation-
ship to cytostasis induced in tumor cells by cyto-
toxic macrophages. J Biol Chem. 1994;269:
21891-21897.
13. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tu-
mor cell ribonucleotide reductase by macro-
phage-derived nitric oxide. J Exp Med. 1991;174:
761-767.
14. Shami PJ, Moore JO, Gockerman JP, Hathorn
JW, Misukonis MA, Weinberg JB. Nitric oxide
modulation of the growth and differentiation of
freshly isolated acute non-lymphocytic leukemia
cells. Leuk Res. 1995;19:527-533.
15. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB,
Schechter AN, Noguchi CT. Erythropoietin and
hypoxia stimulate erythropoietin receptor and ni-
tric oxide production by endothelial cells. Blood.
2004;104:2073-2080.
16. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic
SS, Noguchi CT, Schechter AN. Hydroxyurea in-
duces the eNOS-cGMP pathway in endothelial
cells. Blood. 2006;108:184-191.
17. Yang BK, Vivas EX, Reiter CD, Gladwin MT.
Methodologies for the sensitive and specific mea-
surement of S-nitrosothiols, iron-nitrosyls, and
nitrite in biological samples. Free Radic Res.
2003;37:1-10.
18. Kleinbongard P, Schulz R, Rassaf T, et al. Red
blood cells express a functional endothelial nitric
oxide synthase. Blood. 2006;107:2943-2951.
19. Smith RD, Li J, Noguchi CT, Schechter AN.
Quantitative PCR analysis of HbF inducers in pri-
mary human adult erythroid cells. Blood. 2000;95:
863-869.
20. Huang J, Hadimani SB, Rupon JW, Ballas SK,
Kim-Shapiro DB, King SB. Iron nitrosyl hemoglo-
bin formation from the reactions of hemoglobin
and hydroxyurea. Biochemistry. 2002;41:2466-
2474.
21. Baumann R, Blass C, Götz R, Dragon S. Ontog-
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